血浆犬尿氨酸与正常糖代谢、糖尿病前期及2型糖尿病者认知功能的关联:马斯特里赫特研究
该横断面研究在2358名61±8岁参与者中分析血浆犬尿氨酸与认知功能的关系。在2型糖尿病个体中,多种犬尿氨酸与认知障碍 odds 降低及更好认知功能相关;糖尿病前期中关联较少;正常糖代谢者无关联。
要点
- 2型糖尿病中犬尿氨酸、3-羟基犬尿氨酸、犬尿喹啉酸、黄尿酸和3-羟基邻氨基苯甲酸与认知障碍 odds 降低相关。
- 糖尿病前期中仅3-羟基犬尿氨酸和3-羟基邻氨基苯甲酸与认知障碍 odds 降低相关。
- 正常糖代谢个体中未观察到血浆犬尿氨酸与认知功能的关联。
核心结论
- 在2型糖尿病个体中,多种血浆犬尿氨酸与认知障碍 odds 降低及更好认知功能横断面相关;糖尿病前期中关联较少;正常糖代谢者无关联。
研究设计与样本
- 横断面研究,纳入2358名61±8岁参与者,按糖代谢状态分为正常糖代谢、糖尿病前期和2型糖尿病。
- 采用 logistic、多元线性及限制性立方样条回归分析,校正多种混杂因素。
主要发现
- 糖尿病前期中,3-羟基犬尿氨酸(每 SD OR 0.59 [95% CI 0.37, 0.94])和3-羟基邻氨基苯甲酸(0.67 [0.47, 0.96])与认知障碍 odds 降低相关。
- 2型糖尿病中,犬尿氨酸(0.80 [0.66, 0.98])、3-羟基犬尿氨酸(0.82 [0.68, 0.99])、犬尿喹啉酸(0.81 [0.68, 0.96])、黄尿酸(0.73 [0.61, 0.87])和3-羟基邻氨基苯甲酸(0.73 [0.60, 0.87])与认知障碍 odds 降低相关。
- 2型糖尿病中,犬尿喹啉酸(每 SD β 0.07 [95% CI 0.02, 0.13])和黄尿酸(0.06 [0.01, 0.11])与更好的执行功能/注意力相关。
- 正常糖代谢个体中未观察到上述关联。
临床怎么用
- 对于2型糖尿病个体,低水平犬尿氨酸可能提示认知障碍风险增加,但需进一步研究确认因果及临床价值。
局限性
- 横断面设计无法推断因果关系。
- 研究结论需在其它人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Studies investigating associations between kynurenines and cognitive function have generally been small, restricted to clinical samples or have found inconsistent results, and associations in the general adult population, and in individuals with type 2 diabetes in particular, are not clear. Therefore, the aim of the present study was to investigate cross-sectional associations between plasma kynurenines and cognitive function in a cohort of middle-aged participants with normal glucose metabolism, prediabetes (defined as impaired fasting glucose and/or impaired glucose tolerance) and type 2 diabetes. METHODS: Plasma kynurenines were quantified in 2358 participants aged 61 ± 8 years. Cross-sectional associations of kynurenines with cognitive impairment and cognitive domain scores were investigated using logistic, multiple linear and restricted cubic spline regression analyses adjusted for several confounders. RESULTS: Effect modification by glucose metabolism status was found for several associations with cognitive impairment, hence analyses were stratified. In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0.59 [95% CI 0.37, 0.94]) and 3-hydroxyanthranilic acid (0.67 [0.47, 0.96]) were associated with lower odds of cognitive impairment after full adjustment. In individuals with type 2 diabetes, kynurenine (0.80 [0.66, 0.98]), 3-hydroxykynurenine (0.82 [0.68, 0.99]), kynurenic acid (0.81 [0.68, 0.96]), xanthurenic acid (0.73 [0.61, 0.87]) and 3-hydroxyanthranilic acid (0.73 [0.60, 0.87]) were all associated with lower odds of cognitive impairment. Kynurenic acid (β per SD 0.07 [95% CI 0.02, 0.13]) and xanthurenic acid (0.06 [0.01, 0.11]) were also associated with better executive function/attention. No associations were observed in individuals with normal glucose metabolism. CONCLUSIONS/INTERPRETATION: Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes. Low levels of kynurenines might be involved in the pathway of type 2 diabetes and cognitive decline but this needs further studies.
引用
- Bakker L, Ramakers IHGB, van Boxtel MPJ, et al. Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. Diabetologia. 2021. PMID: 34409496. doi:10.1007/s00125-021-05521-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。